A study of 4,401 adults with type 2 diabetes and chronic kidney disease found that taking a daily dose of canagliflozin was associated with a 34% lower risk of dying from renal causes and 32% lower risk for end-stage kidney disease compared with a placebo. The findings in The New England Journal of Medicine also indicated that canagliflozin treatment was tied to lower risk of cardiovascular death, stroke, heart attack and hospital admission for heart failure.
Study finds lower kidney risk with diabetes drug canagliflozin
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.